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 LETTER TO THE EDITOR 
 Diﬀ erential expression of SHP-1 in chronic myeloid leukemia 
 Jaspal  Kaeda 1 ,  Daniel  Neuman 1 ,  Simone  Bonecker 2 ,  Ken  Mills 3 ,  Christian  Oberender 1 ,  Leila  Amini 1 , 
 Frauke  Ringel 1 ,  Anna  Serra 4 ,  Michaela  Schwarz 1 ,  Bernd  D ö rken 1 ,  Ilana  Zalcberg 2  &  Philipp  le Coutre 1 
 1 H ä matologie, Onkologie und Tumorimmunologie, Medizinische Klinik m.S., Campus Virchow Klinikum, Charit é , 
Universit ä tsmedizin Berlin, Berlin, Germany,  2 Bone Marrow Transplant Center (CEMO), INCA, Rio de Janeiro, Brazil, 
 3 Haematology Research Group, CCRCB, Queens University Belfast, Belfast, UK and  4 Department of Clinical and Biological 
Sciences, University of Turin, Italy 
 Despite the unprecedented success of tyrosine kinase inhibi-
tors (TKIs), the clinical management of 20 – 30% of patients 
with chronic myeloid leukemia (CML) experiencing primary 
or secondary resistance to imatinib mesylate (IM) continues 
to be challenging [1 – 3]. Early identifi cation of these patients 
would indicate a more potent agent upfront, or alternative 
drug following the initial suboptimum response, or stem cell 
transplant (SCT) prior to the subject becoming refractory to 
further treatment. Th erefore, a biomarker with proven clini-
cal utility of predicting patients ’ response to IM would assist 
considerably in optimizing clinical management for such 
patients. Recently, investigators reported that Src homology 2 
domain-containing phosphatase-1 ( SHP-1 ) expression levels 
at diagnosis were prognostic and predictive of TKI response 
in patients with CML [4]. Previously, others suggested that 
down-regulation of  SHP-1 contributes to constitutive acti-
vation of Janus kinase/signal transducer and activator of 
transcription (JAK/STAT) signaling and disrupts protein 
phosphatase 2A (PP2A) mediated  BCR – ABL11 elimination, 
thereby triggering CML transformation [5]. 
 Th erefore, we retrospectively studied 97 cDNA samples 
from patients with highly heterogeneous CML to assess the 
clinical utility of measuring  SHP-1 mRNA levels in patients 
with CML (Table I). Th e samples were collected at various 
time points, refl ected by the overlap in  BCR – ABL1 tran-
script numbers for those who achieved a major molecular 
response (MMR) and those who did not (Table I). Of the 97 
patients, 24 were had advanced disease (AD), i.e. accelerated 
phase (AP)  n    6 and blast crisis (BC)  n    18, and 73 patients 
were in highly heterogeneous chronic phase (CP) treated 
with diff erent modalities. For 35 of the 73 patients in CP the 
MMR status was available for assessing the clinical utility 
of  SHP-1 levels. Among the 24 patients in AD, at least fi ve 
archived serial mRNA samples were available for each of the 
fi ve patients for longitudinal studies. Of these fi ve patients, 
four had been treated with one or more TKIs and one had 
undergone allogeneic SCT. We also included a cohort control 
of 77 diagnostic samples from a group of patients with het-
erogeneous acute myeloid leukemia (AML) and 18 normal 
control samples from adult volunteer blood donors, whose 
characteristics are detailed in Table I. 
 SHP-1 ,  BCR – ABL1 and endogenous control gene,  GUS b , 
transcripts were quantifi ed by real time polymerase chain 
reaction (Q-PCR) as previously reported [6]. Standard curves 
were constructed for each assay using serial log dilutions of 
plasmid, ranging from 1    10 3 to 1    10 6 , with target gene 
specifi c insert.  BCR – ABL1 and  GUS b target sequences were 
included in one plasmid and the other included the  SHP-1 
insert (a kind gift from Professor F. Pane, Naples, Italy). Only 
those samples with    5500  GUS b transcripts were evaluated 
for this report. Non-parametric Mann – Whitney tests were 
performed using PRISM software. 
 Briefl y, 38 of the 73 patients in CP were prescribed single 
agents: (interferon and cytarabine [ n    1]), IM ( n    30), 
nilotinib ( n    6) or dasatinib ( n    1). Th e remainder were 
treated with two or more agents, as were the 24 patients with 
AD.  SHP-1 mRNA was detectable in all samples screened by 
Q-PCR (Table I). However, a signifi cant diff erential in mRNA 
expression ( p    0.0001) was observed between patients in CP 
and the normal control group. Furthermore, the  SHP-1 tran-
scripts were signifi cantly lower ( p    0.0001) in patients with 
AD, with a median of 14.0 (range 0.8 – 211.9), in comparison 
to patients in CP, median 35.7 (range 5.2 – 675.1). Similarly, we 
observed a signifi cant diff erence between patients with CML 
with AD and normal control samples ( p    0.0001). How-
ever, we observed no signifi cant diff erence in  SHP-1 levels 
between AML and normal control samples ( p    0.801). Th is 
is probably explained by the molecular heterogeneity among 
the patients with AML, in contrast to the single genetic lesion 
associated with CML, and that SHP-1 is reported to bind to 
BCR – ABL1. 
 In contrast to published data [4] we found no signifi -
cant diff erence ( p    0.0966) between patients who failed 
to achieve a MMR within 18 months ( n    22) and those 
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patients who did ( n    13). To exclude the possibility that 
the statistical value might have been infl uenced by either 
the highly variable collection time-points or the diverse 
therapeutic agents administered, a restricted analysis of 15 
patients treated with IM alone and for whom we had samples 
collected at diagnosis was performed. Even within this group 
we found no signifi cant diff erence ( p    0.4527), i.e. between 
those who did ( n    6) and failed to ( n    9) achieve MMR 
within 12 months. Th is did not change even when the cri-
terion was extended to 18 months. Th is variance from pub-
lished data may refl ect diff erences in the timing of sample 
collection during the course of treatment in this study and 
that reported by Esposito  et  al . [4]. However, these data do 
not exclude the possibility that assessing SHP-1 activity at 
the protein level would be predictive. Nevertheless, protein 
analysis is too complex for a clinical laboratory to perform, 
in contrast to Q-PCR analysis, and therefore not within the 
scope of this assessment. 
 In addition we noted no signifi cant diff erence in  SHP-1 
mRNA levels between those patients in CP who had been 
prescribed one ( n    37), two ( n    7) or    3 TKIs ( n    8), 
which generally correlated with optimal, suboptimal and/or 
failed response. 
 Th e kinetics data were consistent with overall CP and AD 
results, showing that  SHP-1 levels decreased as the  BCR – 
ABL1 transcript numbers increased, i.e. an inverse rela-
tionship (Figure 1), implying that regulatory control of the 
two is directly or indirectly linked. We did note that for 
patient 4, including the period when the subject was in CP 
(Figure 1), this relationship was not observed. However, 
there was no diff erence of note in this patient ’ s clinical 
history compared to the other four subjects. More impor-
tantly,  BCR – ABL1 transcripts in these fi ve patients were not 
preceded by a decrease in  SHP-1 . 
 Given the relatively low levels of  SHP-1 in comparison to 
 BCR – ABL1 expression, we confi rmed that our assay could 
 Table I. Summary of sample groups. 
Subjects *  n Sex, M/F
Age (years) 
(median)
 BCR – ABL/GUS b 
(median)
 SHP-1/GUS b 
(median)
Normal controls 18 8/10 35 – 61 (44)  — 1.40 – 6.36 (3.66)
AML 77 42/35 8 – 85 (63)  — 0.56 – 13.29 (3.50)
CML: CP 73 44/29 19 – 75 (63) 0 – 1053 (18.38) 5.18 – 675.1 (35.69)
CML: AD  †  24 16/8 34 – 74 (61) 0.40 – 1947 (182.7) 0.82 – 211.9 (14.0)
CML: MMR 13 8/5 20 – 66 (52) 0.24 – 140.30 (7.30) 15.46 – 318.9 (35.69)
CML: f-MMR 22 17/5 19 – 72 (32) 0.0 – 197.60 (62.33) 6.31 – 162.1 (26.72)
 AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CP, chronic phase; AD, advanced disease; MMR, major 
molecular response; f-MMR, failed MMR. 
 * From among the total 97 patients with CML, 13 were classifi ed as having achieved MMR and 22 did not. 
  †  Six accelerated phase, 18 blast crisis. 
 Figure 1. SHP-1 and  BCR – ABL1 kinetics. Kinetics data for  SHP-1 (dashed lines) and  BCR – ABL1 (solid lines) are shown for fi ve patients with 
CML included in the longitudinal study.  Y -axis for  SHP-1 levels is on the right of each graph.  SHP-1 mRNA was detected in all samples tested for the 
fi ve patients and refl ected the  BCR – ABL1 kinetics.  SHP-1 levels did not predict a change in patients ’ disease status, such that an increase or decrease 
in its expression did not precede a change in  BCR – ABL1 transcript levels. Th erefore, we conclude that its predictive value is not superior to that of 
the disease specifi c marker,  BCR – ABL1 . 
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reproducibly detect a fi ve-fold change in  SHP-1 mRNA lev-
els by titrating, in duplicate, the SU-DHL-1 cell line with the 
LAMA-87 hematopoietic cell line. Th is is consistent with the 
generally accepted view that Q-PCR assays have a dynamic 
range of 5-log, although up to an 8-log range is achievable. 
 Th erefore, the kinetics and MMR data suggest that mea-
suring the  SHP-1 mRNA level does not provide additional 
information for identifying patients at risk of disease pro-
gression or predicting response to TKIs beyond that gleaned 
from close regular monitoring by measurement of disease-
specifi c  BCR – ABL1 transcripts. However, the diff erential 
expression of  SHP-1 between CP and AD observed in this 
study was consistent with earlier reports suggesting that 
phosphatase antagonizes  BCR – ABL1 ability to block dif-
ferentiation [7,8]. Reduced expression of  SHP-1 might free 
 BCR – ABL1 to recruit and activate JAK2. Active JAK2 has been 
reported to enhance  β -catenin activity and inactivate PP2A 
mediated degradation of  BCR – ABL1 , thus triggering BC [9]. 
 In conclusion, our data imply that  SHP-1 levels fail to pre-
dict TKI response. However, in keeping with previous reports, 
our data provide further evidence to support the notion that 
 SHP-1 plays a role in CML disease progression. 
 Potential confl ict of interest:  Disclosure forms provided 
by the authors are available with the full text of this article at 
www.informahealthcare.com/lal. 
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